|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun X, Bao J and Shao Y: Mathematical
modeling of therapy-induced cancer drug resistance: Connecting
cancer mechanisms to population survival rates. Sci Rep.
6:224982016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Obenauf AC, Zou Y, Ji AL, Vanharanta S,
Shu W, Shi H, Kong X, Bosenberg MC, Wiesner T, Rosen N, et al:
Therapy-induced tumour secretomes promote resistance and tumour
progression. Nature. 520:368–372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cai Y, Tan X, Liu J, Shen Y, Wu D, Ren M,
Huang P and Yu D: Inhibition of PI3K/Akt/mTOR signaling pathway
enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line
to cisplatin in vitro. Chin J Cancer Res. 26:564–572.
2014.PubMed/NCBI
|
|
7
|
Xie X, Tang B, Zhou J, Gao Q and Zhang P:
Inhibition of the PI3K/Akt pathway increases the chemosensitivity
of gastric cancer to vincristine. Oncol Rep. 30:773–782. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eng C: PTEN: One gene, many syndromes. Hum
Mutat. 22:183–198. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chalhoub N and Baker SJ: PTEN and the
PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fine B, Hodakoski C, Koujak S, Su T, Saal
LH, Maurer M, Hopkins B, Keniry M, Sulis ML, Mense S, et al:
Activation of the PI3K pathway in cancer through inhibition of PTEN
by exchange factor P-REX2a. Science. 325:1261–1265. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leslie NR: P-REX2a driving tumorigenesis
by PTEN inhibition. Sci Signal. 2:pe682009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li
JH, Xu XM, Liu S, Chen J, Liu F, et al: Phosphoinositide
3-kinase/Akt pathway plays an important role in chemoresistance of
gastric cancer cells against etoposide and doxorubicin induced cell
death. Int J Cancer. 122:433–443. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu XQ, Yu JP, Luo HS and Yu HG: The
expression and role of PTEN in doxorubicin induced gastric cancer
cell apoptosis. Zhonghua Nei Ke Za Zhi. 49:422–425. 2010.(In
Chinese). PubMed/NCBI
|
|
14
|
Schmidt N, Peitz U, Lippert H and
Malfertheiner P: Missing gastric cancer in dyspepsia. Aliment
Pharmacol Ther. 21:813–820. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Noh SH, Park SR, Yang HK, Chung HC, Chung
IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, et al: Adjuvant
capecitabine plus oxaliplatin for gastric cancer after D2
gastrectomy (CLASSIC): 5-year follow-up of an open-label,
randomised phase 3 trial. Lancet Oncol. 15:1389–1396. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu BQ and Xie JW: Identifying therapeutic
targets in gastric cancer: The current status and future direction.
Acta Biochim Biophys Sin (Shanghai). 48:90–96. 2016.PubMed/NCBI
|
|
17
|
Ai YW, Yu HG, Yu JP, Yang Y, Li H, Hu XW
and Luo HS: Impact of PI3K/Akt/mdm2 signaling pathway on the
sensitivity of gastric cancer cell line SGC7901 to doxorubicin.
Zhonghua Zhong Liu Za Zhi. 30:494–497. 2008.(In Chinese).
PubMed/NCBI
|
|
18
|
Hu Y, Guo R, Wei J, Zhou Y, Ji W, Liu J,
Zhi X and Zhang J: Effects of PI3K inhibitor NVP-BKM120 on
overcoming drug resistance and eliminating cancer stem cells in
human breast cancer cells. Cell Death Dis. 6:e20202015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Smolensky D, Rathore K and Cekanova M:
Phosphatidylinositol-3-kinase inhibitor induces chemosensitivity to
a novel derivative of doxorubicin, AD198 chemotherapy in human
bladder cancer cells in vitro. BMC Cancer. 15:9272015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Z, Yang L, Xia Y, Guo C and Kong L:
Icariin enhances cytotoxicity of doxorubicin in human
multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and
down-regulation of the PI3K/Akt pathway. Biol Pharm Bull.
38:277–284. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Donald S, Hill K, Lecureuil C, Barnouin R,
Krugmann S, John Coadwell W, Andrews SR, Walker SA, Hawkins PT,
Stephens LR and Welch HC: P-Rex2, a new guanine-nucleotide exchange
factor for Rac. FEBS Lett. 572:172–176. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo B, Liu L, Yao J, Ma R, Chang D, Li Z,
Song T and Huang C: miR-338-3p suppresses gastric cancer
progression through a PTEN-AKT axis by targeting P-REX2a. Mol
Cancer Res. 12:313–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Goler-Baron V, Sladkevich I and Assaraf
YG: Inhibition of the PI3K-Akt signaling pathway disrupts
ABCG2-rich extracellular vesicles and overcomes multidrug
resistance in breast cancer cells. Biochem Pharmacol. 83:1340–1348.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fan QW and Weiss WA: Targeting the
RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr
Top Microbiol Immunol. 347:279–296. 2010.PubMed/NCBI
|
|
25
|
Rasul A, Khan M, Yu B, Ali M, Bo YJ, Yang
H and Ma T: Isoalantolactone, a sesquiterpene lactone, induces
apoptosis in SGC-7901 cells via mitochondrial and
phosphatidylinositol kinase/Akt signaling pathways. Arch Pharm Res.
36:1262–1269. 2013. View Article : Google Scholar : PubMed/NCBI
|
